Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2015 | Single-agent daratumumab activity in refractory multiple myeloma

Maria Victoria-Mateos • 2 Jun 2015
ASCO 2015
Multiple Myeloma Antibodies Daratumumab

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Maria-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, discusses a phase 2 study evaluating single-agent daratumumab activity in patients with heavily pretreated refractory multiple myeloma.

More from Maria Victoria-Mateos

CANOVA trial: VenDex versus PomDex in patients with R/R multiple myeloma
1:53
CANOVA trial: VenDex versus PomDex in patients with R/R multiple myeloma
Maria Victoria-Mateos • 1 Jun 2024
Emerging therapies to address the unmet need for triple-class refractory multiple myeloma
2:17
Emerging therapies to address the unmet need for triple-class refractory multiple myeloma
Maria Victoria-Mateos • 1 Jun 2024
Findings from DREAMM-7 establish belantamab mafodotin as a new SoC for R/R multiple myeloma
2:16
Findings from DREAMM-7 establish belantamab mafodotin as a new SoC for R/R multiple myeloma
Maria Victoria-Mateos • 1 Jun 2024
Prophylactic tocilizumab to mitigate CRS: results from a small cohort in the MajesTEC-1 trial
1:46
Prophylactic tocilizumab to mitigate CRS: results from a small cohort in the MajesTEC-1 trial
Maria Victoria-Mateos • 1 Jun 2024

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Maria Victoria-Mateos • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Maria Victoria-Mateos • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Maria Victoria-Mateos • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Maria Victoria-Mateos • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals